Alembic Pharmaceuticals Limited

NSE APLLTD.NS

Alembic Pharmaceuticals Limited Price to Sales Ratio (P/S) on February 07, 2025: 2.68

Alembic Pharmaceuticals Limited Price to Sales Ratio (P/S) is 2.68 on February 07, 2025, a -20.27% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Alembic Pharmaceuticals Limited 52-week high Price to Sales Ratio (P/S) is 3.91 on August 02, 2024, which is 45.78% above the current Price to Sales Ratio (P/S).
Alembic Pharmaceuticals Limited 52-week low Price to Sales Ratio (P/S) is 2.66 on June 20, 2024, which is -0.83% below the current Price to Sales Ratio (P/S).
Alembic Pharmaceuticals Limited average Price to Sales Ratio (P/S) for the last 52 weeks is 3.29.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NSE: APLLTD.NS

Alembic Pharmaceuticals Limited

CEO	Mr. Chirayu Ramanbhai Amin
IPO Date	Sept. 20, 2011
Location	India
Headquarters	Alembic Road
Employees	14,858
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cosmetics Drugstores & Retail Pharmacies Eyewear Personal Care

Description

Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients and formulations. The company also provides branded and generic formulations in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, and anti-diabetic. In addition, it exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.

Key trends

Past 5 years